XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Details)
 1 Months Ended 3 Months Ended 102 Months Ended
Sep. 06, 2022
USD ($)
Jan. 31, 2014
USD ($)
program
Mar. 31, 2023
USD ($)
product
milestone
Mar. 31, 2022
USD ($)
Jun. 28, 2022
USD ($)
Dec. 31, 2022
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Revenues     $ 157,957,000 $ 28,231,000    
Accounts receivable     7,026,000     $ 3,678,000
Prepaid Expenses and Other Current Assets            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Decrease in research and development expense     500,000      
Sanofi S.A.            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Number of research programs | program   2        
Revenues under agreement   $ 20,000,000        
Revenues     $ 0 $ 1,499,000 $ 13,500,000  
Number of products approved | product     0      
Expenses reimbursable through December 31, 2023 (up to) $ 7,000,000          
Expenses reimbursable after December 31, 2023 (up to) $ 5,300,000          
Sanofi S.A. | Collaboration And License Agreement            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Revenues under agreement         20,000,000  
Number of milestones included in transaction price | milestone     0      
Collaborative arrangement transaction price         96,300,000  
Collaborative arrangement estimated reimbursable service costs         62,800,000  
Accounts receivable     $ 0     0
Contract with customer liability     $ 0     $ 0
Sanofi S.A. | Collaboration And License Agreement | Milestone Three            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Milestone revenue receivable         $ 13,500,000